



<b>Certificate Course in Pharmaceutical Industry for Occasional Students (2023)</b>	
<b>Course Coordinator(s)</b>	Mr. Donald Chong, Honorary Lecturer, Department of Pharmacology and Pharmacy (Email: <a href="mailto:chongd@hku.hk">chongd@hku.hk</a> )  Dr. Aviva Chow, Assistant Professor, Department of Pharmacology and Pharmacy (Email: <a href="mailto:asfchow@hku.hk">asfchow@hku.hk</a> )
<b>Course Description</b>	This course draws on a selection of content from MAPH7320 Introduction to Pharmaceutical Industry to extend the students' overall understanding of the pharmaceutical industry. Through pre-recorded lectures, students will learn about topics such as the brief history of the pharmaceutical industry in Hong Kong, and the industry drivers and trends. There will also be discussion of the various drug development stages, from pre-clinical through to approval. In a pharmaceutical company, platform functions include quality assurance, quality control, production, regulatory affairs, market access, drug safety (pharmacovigilance), medical affairs, clinical research team, and corporate communications. Students will be able to get a clear picture of what each team or department does. This course will cover both the Western and the Chinese medicine aspects though at different depths. Students will be learning from practitioners who are experts in their area of sharing, drawing on years of experience and insight. Speakers range from industry professionals in prestigious multinational companies to private consultants in the industry.
<b>Delivery Mode</b>	Pre-Recorded Lectures and F2F Career Workshop
<b>Assessment</b>	Essay (500 words) – Pass/Fail <ul style="list-style-type: none"><li>• Tentative due date: May 7, 2023</li></ul>
<b>HKU Credits</b>	No – This certificate course is not eligible for application for advanced standing in future enrollment in the Master of Advanced Pharmacy programme.
<b>Certificate of Completion</b>	Yes – Students will receive a certificate of completion upon: <ul style="list-style-type: none"><li>• Completion of pre-recorded videos</li><li>• Attendance at pharmaceutical industry career workshop</li><li>• Achieving pass on essay</li></ul>
<b>Cost</b>	4370 HKD

## Certificate Course in Pharmaceutical Industry (2023)

### Tentative Course Calendar

Date	Time	Delivery Mode	Session Topic	Speaker	Hours
Jan 30 – Feb 5, 2023		Pre-Recorded	General Overview on Pharmaceutical Industry in Hong Kong	Mr Lawrence Wong	1
Feb 6 – Feb 12, 2023			Regulatory Affairs – Its Role & Importance in the Pharmaceutical Industry	Ms Carmen Lai	2
Feb 13 – Feb 19, 2023			Medical Affairs – A Key Role to Relay Medical Information	Ms Mandy Chan	2
			Medical Science Liaison – Translating Science to Convey Values		
Feb 20 – Feb 26, 2023			Bench to Bedside and Beyond	Drs Stijn van den Borne	2
Feb 27 – Mar 5, 2023			Sales and Marketing in the Real-World Practice	Mr Bernard Tang	3
Mar 6 – Mar 12, 2023			Introduction to Pharmacovigilance	Mr Kevin Tai	1.5
Mar 13 – Mar 19, 2023			Market Access and Public Affairs in Pharmaceutical Industry	Ms Ingrid Wong Mr Kay Tse	3
Mar 20 – Mar 26, 2023			Ethics and Compliance in Pharmaceutical Industry	Mr Patrick Tong	1.5
Mar 27 – Apr 2, 2023			Local Manufacturing in HK I	Dr Aviva Chow Mr Ivan Ng	1
Apr 3 – Apr 9, 2023			Local Manufacturing in HK II	Mr Ivan Ng	1
Apr 29, 2023 (Sat)	14:30 – 16:30	F2F	Pharmaceutical Industry Career Workshop	Mr Donald Chong	2

### Course Coordinators

Speaker	Biography
Mr. Donald Chong	<p>Donald Chong, BSc (Pharmacy, University of British Columbia, Canada) and MBA (Health Services Management, University of Hull, U.K.) is currently the Regulatory Affairs Director of GlaxoSmithKline Consumer Healthcare (Hong Kong) Limited. Besides being a licensed pharmacist in both Hong Kong and Canada, he is a Certified Master NLP Coach awarded by the American Association of NLP (Neurolinguistic Programming). He is also a certified coach awarded by the Worldwide Association of Business Coaching. Besides his regular work, he has myriad contribution in coaching, patient education and university teaching experience. He is presently honorary lecturer of the University of Hong Kong (HKU) and helps develop courses relating to the pharmaceutical industry. Besides he is the preceptor for the pharmacy students at the School of Pharmacy at the Chinese University of Hong Kong as well as the HKU. He has also been invited by various patient associations and hospitals to deliver training of various kinds over the past few years. More noticeably, he is the course developer for the course “Understanding Western Medicine” at the Open University of Hong Kong. In his leisure time, he also contributes articles to the Hong Kong Pharmaceutical Journal in areas such as diseases and treatments as well as more lately in leadership and coaching. He is currently the section editor of the Pharmacy Practice and Education of the journal. With his experience of over 25 years in the pharmaceutical industry, he wishes to make more positive impact to other people’s lives and well-being through coaching and teaching.</p>
Dr. Aviva Chow	<p>Dr Chow is an Assistant Professor in the Department of Pharmacology and Pharmacy in the University of Hong Kong (HKU). Dr. Aviva Chow obtained his Bachelor degree of Chemical and Bioproduct Engineering from the Hong Kong University of Science and Technology (HKUST). He pursued his PhD in Pharmacy (Pharmaceutical Sciences) at the Chinese University of Hong Kong (CUHK). Prior to joining HKU, Aviva worked as a technical lead and research scientist at Jacobson Pharma Corporation Limited. He is also one of the principal investigators in Advanced Biomedical Instrumentation Centre (ABIC) at the Hong Kong Science and Technology Park.</p>

### Speaker Team

Speaker	Biography
Ms. Mandy Chan	<p>Mandy holds a Bachelor of Pharmacy degree and Master of Science degrees in Epidemiology and Biostatistics from the Chinese University of Hong Kong. As a registered pharmacist, Mandy demonstrated the important role of pharmacist in MNC pharmaceutical companies, especially in Medical Affairs, Medical Science Liaison and Medical Information. Mandy will share the essential skills needed to excel in Medical Function during the course.</p>



Ms. Carmen Lai	Carmen is a qualified pharmacist in Canada and Hong Kong with over 15 years of regulatory experience in leading regional/local regulatory strategy programs within the biopharmaceutical sector in Asia Pacific (APAC) region. As Senior Regulatory Affairs Manager of Amgen Hong Kong Limited, she has proven track record of biopharmaceutical product registrations and clinical trial applications/notifications (CTAs/CTNs) for Hong Kong & South East Asia countries. Prior to joining Amgen, she worked at Hospira, managing regulatory, quality and pharmacovigilance activities for generic pharmaceutical products and medical devices in China and Hong Kong. Carmen is a clinical pharmacist by training where she previously practiced at the Scarborough Hospital, Canada, specialized in cardiology, medicine and surgery. She holds a Bachelor of Science degree in Pharmacy from the University of Toronto, Canada.
Mr. Ivan Ng	Ivan is a registered pharmacist who obtained his Bachelor Degree in Pharmacy from the Chinese University of Hong Kong. He is also a registered Authorized Person of a PIC/S GMP manufacturer of generic medicines. Being the QA Manager, he oversees production, quality control and regulatory affairs to ensure that products are manufactured in accordance to the PIC/S Good Manufacturing Practice (GMP) and Hong Kong regulatory requirements.
Mr. Kevin Tai	Kevin is currently the Senior Regional Pharmacovigilance (PV) Officer in Asia Pacific region at MSD. He has 8 years of experience in drug safety at the local and regional level in the pharmaceutical industry setting including case processing, regulatory compliance, PV agreement management, PV training, and audit/inspection readiness etc. His strong passion in PV is driven by finding solutions to streamline internal processes to establish compliance standards as well as to meet the external PV requirements from health authorities. Kevin holds a BSc in Toxicology from the University of Toronto, a BSc in Pharmacy from the University of British Columbia, and an MBA from the Hong Kong Polytechnic University. He is also a registered pharmacist in Canada.
Mr. Bernard Tang	Bernard holds a Bachelor of Pharmacy degree from King's College London and is a registered pharmacist in the UK and Hong Kong. He has earned an Executive MBA from Imperial College London, specialized in Healthcare Industry. In career, he is trained and worked as Clinical pharmacist at a London teaching hospital focused in cardiology with a Certificate of Clinical Pharmacy Practice. He also enriched his work experience in community pharmacy in UK and HK. In recent 10 years, he has held different commercial positions with marketing and business development roles in various MNC such as Pfizer, AbbVie, Amgen, covering Rheumatology, Immunology, Paediatrics, Oncology and Haematology areas.
Mr. Patrick Tong	Patrick holds a Bachelor of Commerce degree from the University of Calgary, and he possesses a US CPA qualification. He has over 20 years of audit and compliance experience in different industries such as healthcare, oil & gas, semi-conductor, retail, etc. In recent 10 years, he focuses his career within the pharmaceutical and healthcare industry which he worked for different multi-national companies such as Pfizer, Johnson & Johnson, Takeda, etc.
Mr. Kay Tse	Kay is a registered pharmacist in Hong Kong. He holds a Bachelor of Pharmacy and a Master of Public Health degree. His experience in the pharmaceutical industry include medical affairs, pharmacovigilance and market access. He has worked for multiple well-recognized pharmaceutical companies such as Pfizer, Takeda and Roche. Currently, he is focused on market access and has played critical role in introducing new drug to the HA drug formulary.



<p>Drs. Stijn van den Borne</p>	<p>Drs Van den Borne obtained his degree in Biomedical Sciences from the University of Amsterdam in 2003 with a GPA of 8/10. After graduating, Mr Van den Borne took a course in Good Clinical Practices, before joining Kendle International (now INC Research - a Contract Research Organisation [CRO]) as Clinical Research Associate, to be immediately outsourced to Pfizer Netherlands supporting various oncology and cardiovascular clinical research projects. In 2007, he transitioned to Hong Kong SAR to join the local Pfizer affiliate as the Associate Manager Clinical Research (Projects) and later as the Oncology Research and Scientific Specialist, a Medical Liaison function, sharing responsibility for the local medical strategies for marketed and pipeline oncology products with Medical Affairs.</p> <p>After leaving Pfizer in 2012, he joined a startup CRO named TRE APAC Ltd in the capacity of Project Manager. TRE APAC Ltd was a research organisation directly linked to a non-profit organisation named the Organisation for Oncology and Translational Research (OOTR) with offices in Hong Kong and Kyoto. His responsibilities included setting up non-industry sponsored clinical research studies, medical writing of study proposals and research protocols, as well as writing about research in general. In 2016 Mr Van den Borne left TRE APAC Ltd and started medical writing, first as a freelancer but eventually he opened an office in 2019 hiring his first staff. The company - initially named MediPaper Medical Communications Ltd and now rebranded to [‘mediPr] - currently has 13 staff and serves doctors, healthcare organisations, and the pharmaceutical and medical devices industries in the production of various medical communications including manuscript writing.</p>
<p>Ms. Ingrid Wong</p>	<p>Ingrid Wong is an enthusiastic leader in the fields of market access and public affairs, having worked in various world leading pharmaceutical companies, medical device companies and consulting firms in Hong Kong and the UK in the past 14 years. Her current focus, as a regional advocacy lead, is on policy shaping in the Asia Pacific region and leading projects which involve the advancing primary care system for non-communicable disease management and use of AI-empowered predictive algorithm to improve public health outcome. Academically, she is now a Doctor of Public Health candidate in Johns Hopkins University, having obtained a Master of Philosophy degree in Pharmacology from the Chinese University of Hong Kong and another Master of Philosophy degree in Bioscience Enterprise from the University of Cambridge.</p>
<p>Mr. Lawrence Wong</p>	<p>As the General Manager of Ferring Pharmaceuticals Limited in Hong Kong since 2016, Lawrence is responsible for all commercial operations. Prior to this position, he has been working in the company in various roles including marketing, sales, management, and business development, in both local and APAC regional scopes. Throughout the period, he was involved in continued interactions with different stakeholders in the industry, in particular with healthcare professionals in Hong Kong for academic and scientific collaborations.</p> <p>Lawrence is also the Vice President of the Hong Kong Association of Pharmaceutical Industry (HKAPI), following previous role as a Board member in two consecutive terms of 2018–20 and 2020–22, leading task forces to foster R&amp;D eco-system and to expedite medical advancements respectively. He is also member of Joint Management Committee for GMP Cell Processing Facility with PIC/S GMP (HKSTP, CUHK), a member of Assessment Panel for HKSTP Clinical Translational Catalyst (CTC) and Panel Member of the Pharmacy and Poisons Appeal Tribunal, Department of Health, The Government of Hong Kong SAR. Lawrence holds a BSc Degree in Biochemistry from the University of Hong Kong, and an MBA Degree from the University of London (International Programme).</p>